Greg Patti's practice includes substantial experience in mergers and acquisitions and corporate governance, with a particular focus on negotiated and contested mergers and acquisitions, restructurings, spin-offs, joint ventures, proxy contests and other complex financings. Greg represents foreign and domestic entities in cross-border business transactions and counsels clients on divestitures, private equity transactions, and auctions of large subsidiaries and divisions of public companies.
In addition to his transactional practice, Greg counsels clients on a broad range of business-related matters including securities law, directors' duties and responsibilities, disclosure issues and compliance. Greg has represented portfolio companies, public and private acquirors, targets and investment banks. He has advised clients on numerous significant matters, particularly in the life sciences and telecom industries.
Greg is a founder of the Shareholder Director Exchange (SDX ), a working group of leading independent directors and representatives from some of the largest and most influential long-term institutional investors. Advised by Cadwalader, the working group created the SDX Protocol as a template to assist U.S. public company boards and institutional investors in addressing corporate issues as normal course of business.
Before joining Cadwalader, Greg was a partner at O'Melveny & Myers. Greg Patti received his J.D. from Harvard Law School, an M. Phil. in International Relations from the University of Cambridge, and a B.A., magna cum laude, from Yale University.
•Salix Pharmaceuticals, Ltd. in its $15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.
•Acorda Therapeutics, Inc. in its pending acquisition of Civitas Therapeutics, Inc.
•The Medicines Company in its agreement to divest three of its marketed cardiovascular products and related assets to Chiesi Farmaceutici S.p.A., for up to $792 million.
•The Medicines Company in connection with the public offering of $402.5 million of convertible senior notes, due 2023.
•Forbes Media LLC on its pending sale of a majority stake to a group of international investors as part of the Company's global growth strategy.
•elan Corporation in its $8.6 billion sale to Perrigo Company plc.
•elan Corporation in its successful defense of a $6.6 billion hostile tender offer by Royalty Pharma.
•elan Corporation in the spinoff of its subsidiary, Prothena Corporation plc.
•United States Treasury Department in the restructuring of General Motors
•J.P. Morgan Capital Partners, LLC in the $440 million sale of its MQ Associates, Inc. medical diagnostic imaging business to Novant Health
•Sun Healthcare Group, Inc. in the $625 million acquisition of Harborside Healthcare Corporation from an affiliate of Investcorp
•Verizon Communications in the sale of its Latin American directories business to an affiliate of Welsh, Carson, Anderson & Stowe
•Sun Healthcare Group, Inc. in the sale of its home health care business to AccentCare, Inc
•Dynegy, Inc. in the $2.4 billion sale of its natural gas liquids business to an affiliate of Warburg Pincus
•Verizon Communications in the $1.5 billion sale of its Canadian directories business to an affiliate of Bain Capital
•Verizon Communications in the sale of the healthcare information technology business of its Verizon Information Technologies Inc. subsidiary to Infocrossing, Inc.
•Sun Healthcare Group, Inc. in the sale of its pharmacies business to Omnicare, Inc.
•Verizon Communications in the sale if its BBNT Solutions subsidiary to an affiliate of General Catalyst Partners and Accel Partners
•Qwest Communications International Inc. in the $7.05 billion sale of its QwestDex directories business to an affiliate of The Carlye Group and Welsh, Carson, Anderson & Stowe
•Verizon Communications in the $800 million sale of its TSI Telecommunication subsidiary to an affiliate of GTCR Golder Rauner
•GTE Corp. in the acquisition and sale of approximately $4.5 billion in cellular properties from and to Alltel Corporation
•Telecom Italia Mobile in the acquisition of a Venezuelan cellular company
• Cadwalader Represents The Medicines Company in its Private Offering of $402, 500, 000 Convertible Senior Notes Due 2023
Jun 16, 2016
• Cadwalader Recognized by The American Lawyer With Two 2014 Global Legal Awards
Jul 11, 2014
Clients & Friends Memos
• Del Monte Decision Enjoins Shareholder Vote and Deal Protections; Holds Buyer Potentially Responsible for Aiding and Abetting Seller Board's Fiduciary Breach
Feb 18, 2011
• Tainting The Sales Process
Mar 18, 2011
• Second Annual SDX Symposium
Nov 16, 2015